Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00294502 · ClinicalTrials.gov registry record · Phase 4

Antibiotic Lock Solutions in the Prevention of Catheter Related Bacteremia

A Phase 4 study, sponsored by Henry Ford Health System.

Completed
Registry status
Phase 4
Development phase
120
Enrollment target

NCT00294502 is a Phase 4 study that has completed, run by Henry Ford Health System. The registered enrollment target is 120 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00294502, a Phase 4 study, has completed, sponsored by Henry Ford Health System.

COMPLETED
Registry status
Phase 4
Development phase
120 participants
Enrollment target

Study Summary

To study the efficacy of an antibacterial/anticoagulant solution instilled into the hemodialysis (HD) catheters after each treatment ("antibiotic lock solution - ALS") to prevent catheter related bacteremia (CRB) and to salvage catheters with established CRB.

Interventions

  • DRUG Gentamycin/citrate, Minocycline/EDTA

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2003-09
Est. Completion 2004-05
Phase Phase 4

Sponsor

Henry Ford Health System

234 total trials

What the Registry Record Tells You About NCT00294502

The ClinicalTrials.gov registry entry for NCT00294502 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Gentamycin/citrate, Minocycline/EDTA is the first listed.

NCT00294502 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00294502 about?

NCT00294502 is a clinical study titled "Antibiotic Lock Solutions in the Prevention of Catheter Related Bacteremia". To study the efficacy of an antibacterial/anticoagulant solution instilled into the hemodialysis (HD) catheters after each treatment ("antibiotic lock solution - ALS") to prevent catheter related bacteremia (CRB) and to salvage catheters with established CRB.

What is the current status of trial NCT00294502?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 120 participants. The study started on 2003-09. Estimated completion is 2004-05.

What interventions are being tested in trial NCT00294502?

The interventions under investigation include: Gentamycin/citrate, Minocycline/EDTA (DRUG).

Who is sponsoring clinical trial NCT00294502?

This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.